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Summary Although, the ﬁrst-generation drug eluting stents (DES) have signiﬁcantly reduced
rates of restenosis compared to bare metal stents (BMS), an increased risk of late stent throm-
bosis (LST) has emerged as a major concern. Pathologic studies of patients dying from late DES
thrombosis demonstrates delayed arterial healing characterized by persistent ﬁbrin deposition
and poor endothelialization as the primary substrate. However, recent thorough investiga-
tions revealed additional mechanisms of stent thrombosis such as hypersensitivity reaction,
excessive ﬁbrin deposit with malapposition, or neoatherosclerosis, which are associated with
device-speciﬁc components and the majority of very late stent thrombosis is likely associated
with these abnormal vascular responses. Therefore, although the incidence of stent thrombosis
following DES implantation is similar in each period, the underlying mechanisms of this compli-
cation may vary. In the current review, the mechanisms of stent thrombosis in the DES era will
be discussed using the data from autopsy studies that have been published.
© 2011 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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Introduction
The ﬁrst-generation polymer-based sirolimus (Cypher, Cordis
Corporation, Miami, FL, USA) and paclitaxel (Taxus, Boston
Scientiﬁc, Natick, MA, USA) drug-eluting stents (DES) have
signiﬁcantly reduced rates of restenosis compared to bare
metal stents (BMS) and have quickly become the stan-
dard of care for coronary artery disease [1—3]. However,
the overwhelming success was overly enthusiastic before
a number of clinical case reports began to raise concerns
about an increased risk of late stent thrombosis (LST),
which was infrequently seen with BMS. Subsequently, sev-
eral presentations at the European Society of Cardiology
(ESC) meeting in 2006 such as the BAsel Stent Kosten Effek-
tivitäts Trial — LAte Thrombotic Events (BASKET-LATE) trial
demonstrated higher rate of cardiac death and non-fatal
myocardial infarction (MI) in DES vs. BMS following discontin-
uation of clopidogrel at 6 months with 18 month follow-up
(4.9% vs. 1.3%; p = 0.01) [4]. These studies had a tremen-
dous impact on the interventional cardiology community
since it was generally believed that DES are undeniably ben-
eﬁcial and safe as they dramatically reduced restenosis.
A number of studies have shown that there is no statis-
tical difference in mortality between DES and BMS since
the impact of late stent thrombosis on mortality is bal-
anced by a reduction in restenosis compared with BMS [5].
Later, a large number of meta-analyses and registry stud-
ies were presented at the US Food and Drug Administration
(FDA) meeting in Washington DC, USA on the subject of DES
safety. A consensus was reached that there was an increased
risk of LST following DES implantation in the setting of
‘‘off-label’’ use such as bifurcation, long lesions (>30mm),
saphenous vein bypass graft, left main disease, chronic total
occlusion, renal failure, and acute myocardial infarction
(AMI). Therefore, a recommendation was made to extend
the use of dual-antiplatelet therapy for 1 year following
DES implantation. Nonetheless, the clinical data con-
tinue to provide conﬂicting results regarding the safety of
DES.
Interpretation of clinical data
Based on the clinical data, one can say that the con-
cern of LST has been overcome since many clinical studies
have shown no statistical signiﬁcance in the rate of LST
between DES and BMS. However, one criticism of these
large-scale clinical trials and meta-analyses was that they
lacked accuracy in the detection of stent thrombosis as
investigators had used varied deﬁnitions of when and how
to diagnose LST and cardiac death. Therefore, the ARC
(Academic Research Consortium) deﬁnition was proposed to
standardize the deﬁnition of stent thrombosis and provide
consistency in the reporting of these events [6]. In brief,
‘‘deﬁnite’’ stent thrombosis requires angiographic or patho-
logic conﬁrmation of thrombosis in a stented segment, while
‘‘probable’’ stent thrombosis is deﬁned as any unexpected
death within the ﬁrst 30 days or any MI that is related to
a documented acute ischemic event in the territory of the
implanted stent without angiographic conﬁrmation of stent
thrombosis. ‘‘Possible’’ stent thrombosis is deﬁned as any
unexplained death >30 days following stent placement until
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he end of trial follow-up. Since LST (i.e. >30 days) is the
ost common complication in DES, it is not entirely rea-
onable to deﬁne any unexplained death beyond 30 days as
‘possible’’. Also most of the clinical studies do not report
r emphasize on ‘‘possible’’ stent thrombosis. Furthermore,
‘deﬁnite’’ LST (>30 days) requires angiographic conﬁrma-
ion which means that these patients with LST have to reach
he hospital. However, considerable numbers of patients die
uddenly from abrupt occlusion of the coronary arteries by
ST and do not make it to the hospital, therefore result-
ng in an underestimation of LST. There is no doubt that
utopsy is essential to prove the presence of thrombus in
atients dying >30 days after stent implantation, given that
he rate of autopsy worldwide is less than 2—3%, it should be
andated to include autopsy or at least partial autopsy (i.e.
imited to hearts or removal of stented artery) in the request
orms of signed consent for a patient’s inclusion into these
linical trials. Of note, in our autopsy registry of DES, more
han 30% of patients who died >30 days following stent place-
ent had a documented ‘‘stent-related-death’’ as a cause
f death, predominantly LST. Only autopsy studies, focused
n detailed histologic analysis of the stented artery and
yocardium, can unequivocally prove the presence of LST.
herefore, the ARC deﬁnition, although the most ‘‘unifying’’
eﬁnition at present, can easily obscure the data, espe-
ially when the study directors cannot obtain individual
ata. Cutlip et al. have stated in their publication, ‘‘the
ategories of probable and possible stent thrombosis add
uch sensitivity but the utility of these categories will vary
epending on the quality of data available to the adjudica-
ion committee’’ [6]. More recently our group from CVPath
nstitute, Inc. have collaborated with Dr. Cutlip’s group to
alidate the accuracy of ARC deﬁnition among the autopsy
opulation [7]. Although prevalence of stent thrombosis at
utopsy is extremely higher than that in a regular popu-
ation, the sensitivity of ARC ‘‘deﬁnite’’ and ‘‘probable’’
as as low as 51% whereas it increased up to 92% when the
‘possible’’ was included but at a cost of reducing speciﬁcity
o 34%. Therefore, we have added a new category termed
‘ARC modiﬁed possible’’ including only those cases classi-
ed as sudden death or acute ischemia likely, which resulted
n improved speciﬁcity over the current ARC possible
riteria.
Currently, use of hard endpoints such as death and
yocardial infarction is preferable to determine the safety
f these devices due to the reasons stated above. Moreover,
t should be also noted that some studies have reported
nly cardiac death but not on all-cause death, which has
ed to an underestimation of late events related to DES,
ince these classiﬁcations are highly dependent on the
vent adjudication committee. As Camenzind et al. pointed
ut, Cypher clinical programs reported all-cause deaths,
hereas most Taxus clinical programs included only adju-
icated cardiac death [8]. According to the analysis by
amenzind et al., higher mortality rates were documented
oth in Cypher and Taxus DES as compared to respective
MS control when all-cause death was included [8]. There-
ore, in order to determine the safety of DES, we need
arge patient registries or randomized trials with one def-
nition of LST which includes all ‘‘deﬁnite,’’ ‘‘probable,’’
nd ‘‘possible’’ with the latter two having similar
eight.
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inding from autopsy — 1st generation DES
r. Virmani and colleagues were the ﬁrst to report incom-
lete endothelial coverage with focal platelet aggregates
nd persistent ﬁbrin deposition within the necrotic core
t 16 months following Cypher stent implantation in 2003
9]. In 2006, they reported delayed arterial healing in DES,
s characterized by persistence of ﬁbrin, incomplete re-
ndothelialization, and sparse smooth muscle cell coverage
ompared with BMS implanted for similar duration [10]. LST
as observed in 14 of 23 patients receiving Cypher or Taxus
ES. Although neointimal thickening was minimal in DES,
oor endothelial cell coverage of the lumen was consistently
ocumented in all DES cases regardless of the duration of
mplantation, while endothelialization was complete by 3—4
onths in BMS. Later, a lack of endothelial strut coverage
as reported as the best correlate of LST using the data from
larger number of autopsy cases [11]. The arterial healing
n DES lesions was heterogeneous, especially in thrombosed
ases, suggesting that the underlying lesion morphologies
lso contribute to the rate of healing. We have recently
g
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igure 1 Histologic sections in the top row (A, B, and C) are from p
ho died from congestive heart failure 9 months after Taxus stent im
ause 13 months after Cypher stent implantation (B), and a 34-yea
fter Cypher stent implantation (C). Struts with necrotic core (NC) w
overage (A). Stents in (B) and (C) showed minimal coverage of stru
ections in the bottom row (D, E, and F) are from patients with st
ause 7 months after Cypher stent implantation (D), a 53-year-old ma
E), and a 68-year-old male who died from a non-cardiac cause 19
nderlying ﬁbroatheroma with thick ﬁbrous cap (FC). High magniﬁ
egrees of neointimal formation above stent struts (D, E, and F).
eproduced, with permission, from Nakazawa et al. [13].G. Nakazawa
eported that DES applied for ‘‘on-label’’ indication has
hown much faster healing than those for ‘‘off-label’’ [12].
sage of DES in AMI patients
ne of the underlying plaque morphologies associated with
reater incidence of LST is ruptured plaques, which are fre-
uently observed in patients with AMI. We have observed
signiﬁcantly higher incidence of LST in patients treated
ith DES for AMI as compared to those for stable lesions at
utopsy [13]. Furthermore, we have observed heterogene-
ty of healing in AMI patients at culprit sites (i.e. site of
nderlying plaque rupture) with further delay of healing as
ompared to non-culprit sites (i.e. away from the plaque
upture site) (Fig. 1). These culprit lesions speciﬁcally
howed greater ﬁbrin deposition, greater inﬂammation, and
reater incidence of uncovered struts compared with other
esions, suggesting that underlying plaques do play an impor-
ant role in vascular healing following DES. Although it is not
nown how plaque morphology affects healing, there are
atients with acute myocardial infarction. A 64-year-old female
plantation (A), a 49-year-old male who died from non-cardiac
r-old female who died from late stent thrombosis 24 months
ere observed with ﬁbrin deposition and absence of endothelial
ts above necrotic core at 13 or 24 months duration. Histologic
able lesions. A 61-year-old male who died from a non-cardiac
le who died suddenly 18 months after Taxus stent implantation
months after Cypher stent implantation (F). All patients had
cation images show underlying NC and thick FC with varying
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several likely possibilities. Since sirolimus and paclitaxel are
highly lipophilic [14], it is likely that these agents have high
afﬁnity for lipid-rich plaques (i.e. necrotic core) and dwell
there for longer periods of time as compared to ﬁbrotic types
of plaque. In addition, the lipid-rich necrotic cores are more
avascular compared to the more ﬁbrous dominant regions of
plaques and have fewer cells. Therefore these areas are less
likely to be covered by migrating and proliferating cells from
adjacent areas. Ruptured ﬁbrous caps are either devoid of
smooth muscle cells or are thinly populated with smooth
muscle cells [15]. Higher drug concentrations in these areas
may also heavily inﬂuence healing by retarding smooth mus-
cle cell proliferation as well as endothelial re-growth. In
addition, thrombus burden may also play a role by increas-
ing uptake of drug by the thrombus as shown by Hwang et al.
with paclitaxel eluting stents [16].
Although several clinical studies have demonstrated sim-
ilar incidence of stent thrombosis between DES and BMS
in patients with AMI [17] even after long-term follow-
up [18,19], clinicians should still be cautious because of
the pathological ﬁndings as mentioned above. Kubo et al.
reported that the lack of neointimal strut coverage was
more frequently observed in the patients with unstable
angina compared to those with stable angina, which is con-
sistent with the ﬁndings at autopsy [20]. Also it may not
be prudent to implant DES in emergent procedure, which
requires dual antiplatelet therapy at least for 1 year, with-
out knowing the patients backgrounds such as having cancer
with planed operations, poor compliance, or allergy to anti-
platelet drugs. Furthermore, data from the J-Cypher registry
revealed that the rate of patients who needed to receive a
minor or major operation reached as high as 14.7% within 3
years [21]. Therefore, it is still controversial to apply DES to
patients with AMI.
Speciﬁc reaction to 1st generation DES as a
cause of stent thrombosis
Not only underlying patient and lesion factors, but also
devices themselves affect vascular healing and response.
Although both of 1st generation DES, Cypher and Taxus, have
dramatically reduced the rate of restenosis as mentioned
above, the reaction to these two types of DES is fundamen-
tally different.
Virmani et al. have reported the ﬁrst case of LST
cause by localized hypersensitivity reaction who died 18
months after Cypher stent implantation [22]. The morpho-
logic changes were localized to the area of the stent and
consisted predominantly of CD45-positive lymphocytes and
eosinophils. The vessel in the stented segment was dilated
with occasional formation of coronary aneurysm. Our obser-
vations revealed that this phenomenon is limited to the
Cypher, but not Taxus stent [12]. Since pharmacokinetic
studies in animal models have shown that the drug is com-
pletely released from Cypher stent by 60 days [23], we
deduced that the reaction was likely related to the non-
erodable polymer. Cypher stents are coated with a thin
layer of a poly-n-butyl methacrylate and polyethylene-vinyl
acetate copolymer containing sirolimus. In studies unre-
lated to stents, poly-n-butyl methacrylate, a component of
bone cement (and of the polymer on Cypher stent) when
i
A
f87
mplanted subcutaneously promotes macrophage and giant
ell reaction along with ﬁbrosis [24]. Also polyethylene-vinyl
cetate, (another component of the Cypher polymer), when
sed as an antigen-delivery matrix, has been shown to cause
nﬂammation in 25% of rabbits. Even in preclinical studies
sing the pig model, there is a progressive increase in the
resence of granulomatous reactions including eosinophilic
nﬁltrate starting at 28 days after Cypher stent implantation
25].
Because of lack of systemic symptoms, it is difﬁcult
o detect DES-induced hypersensitivity reactions in the
linical setting. Late positive vessel remodeling and incom-
lete apposition has been reported to occur in 8.7% of
atients with Cypher stents [26]. Although, the incidence
f hypersensitivity reaction in patients with acquired posi-
ive remodeling after Cypher and Taxus stent implantation
s unknown, it is possible that some of these patients have a
ypersensitivity reaction. Recently, Imai et al. surveyed the
mpact of peri-stent contrast staining (a new angiographic
nding where contrast staining was seen outside the stent
truts but not fulﬁlling the deﬁnition of coronary aneurysm)
nd found that the cumulative incidence of target-lesion
evascularization and deﬁnite very late stent thrombosis at
years was higher in patients with peri-stent contrast stain-
ng than those without (15.0% vs. 6.5%, and 8.2% vs. 0.2%,
espectively) [27]. Thus, there are some clues of this com-
lication which can be detected by careful clinical practice.
owever, there is no speciﬁc treatment for patients with
bvious hypersensitivity reaction at the moment.
On the other hand, extensive ﬁbrin deposition with or
ithout stent malapposition is observed only with Taxus
tents (although mild ﬁbrin deposition can be seen in
ny DES) [12]. Our ﬁnding of greater ﬁbrin accumulated
round struts in Taxus remains consistent with the vascu-
ar responses seen in prior preclinical studies. For example,
arb et al. showed a dose-dependent increase in ﬁbrin
eposition and medial necrosis following deployment of
aclitaxel-eluting stents in rabbit iliac arteries [28], and
imilar dose escalatory ﬁndings were reported in the porcine
odel [29]. Therefore, although it is unclear how the Taxus
olymer SIBBS [poly (styrene-b-isobutylene-b-styrene)] con-
ributes to these observations, we believe that paclitaxel
tself is responsible for excessive ﬁbrin deposition. Further-
ore, arterial healing is more heterogeneous in Taxus than
ypher at autopsy [12] and a similar ﬁnding was reported
y Awata et al. where they assessed stent strut coverage
nd surface condition using coronary angioscopy [30]. This
uggests that the effect of paclitaxel is largely affected by
nderlying plaques and the optimal therapeutic range of
aclitaxel appears to be very narrow.
Thus, these speciﬁc reactions to each DES can be associ-
ted with the risk of late events such as late restenosis or
tent thrombosis, if the reaction is excessive (Fig. 2). These
ndings would give some hints to improve intra-coronary
evices for the next generation.
xaggerated neoatherosclerosis following DES
mplantation
s previously reported, mechanism(s) of LST are likely multi-
actorial [10]. Recently, another abnormal vascular response
88 G. Nakazawa
Figure 2 (A) Histologic sections from sirolimus-eluting stent (SES). A 40-year-old female, who received 2 SES in the left anterior
descending artery (LAD) and right coronary artery (RCA) 17 months antemortem, died suddenly 4 days following surgical removal
of melanoma (wide excision). Anti-platelet therapy (aspirin and clopidogrel) was discontinued 5 days before the surgery. Histologic
sections of the SES in LAD showed total thrombotic occlusion and diffuse inﬂammation (a). Numerous inﬂammatory cells were
observed within the neointimal area (b). Inﬂammatory reaction predominantly consists of T-lymphocytes (c; CD45Ro) and eosinophils
(d; Luna stain). Note, the same reaction was observed in the SES in RCA (e) and severe inﬂammation resulted in malapposition of
stent struts (f). (B) Histologic sections from paclitaxel-eluting stent (PES) showing malapposition. A 69-year-old male, who received
PES in saphenous vein graft, died suddenly 3 months after the stent placement. Histologic sections showed thrombotic occlusion
in the PES (a and b); note, malapposition secondary to severe ﬁbrin deposition (c). A 48-year-old male with PES implantation in
the proximal LAD died suddenly at 40 months. Histologic sections showed thrombotic occlusion of the PES (d). Most struts are
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ﬁalapposed with ﬁbrin deposition underneath the stent struts (
eproduced, with permission, from Nakazawa et al. [12].
hat might be associated with LST was noted at autopsy.
e have observed the newly formed atherosclerotic change
ithin the neointimal tissue of stented segments, so called
‘neoatherosclerosis’’ (Fig. 3) [31]. From the autopsy reg-
stry, all available material, which includes 299 consecutive
utopsy cases (142 BMS, 157 DES patients) with 406 lesions
f >30 days’ implant duration (197 BMS, 209 DES lesions)
t
a
rd f). Thr, thrombus.
as reviewed. Atherosclerosis of the neointima within the
tent (i.e. neoatherosclerosis) was deﬁned as peri-strut
oamy macrophage clusters with or without calciﬁcation,
broatheromas, thin-cap ﬁbroatheromas, and plaque rup-
ures but no communication with the underlying native
therosclerotic plaque. The incidence of any neoatheroscle-
osis was greater in DES (31%) than BMS (16%) lesions
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Figure 3 Histologic sections with Taxus stent implanted in the left circumﬂex artery 14 months antemortem. A low power image
shows a patent lumen with moderate neointimal growth (A), foamy macrophage inﬁltration and necrotic core formation with
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mcholesterol clefts is seen at high magniﬁcation in (B). Histolog
low power image shows in-stent restenosis (C), necrotic core fo
(p < 0.001). Nearly half the DES lesions with neoatheroscle-
rosis (48%) contained peri-strut foamy macrophage clusters
and the other half showed ﬁbroatheromas with necrotic core
formations. A signiﬁcant temporal relationship was found
among BMS and DES; atherosclerotic change occurred in
signiﬁcantly shorter implant durations for DES than BMS
(DES, 420 [361,683] days; BMS, 2160 [1800,2880] days;
p < 0.001). For those implants of 2 years or less, the DES
group had a greater incidence of any neoatherosclerosis
(DES = 29% vs. BMS = 0%, p < 0.001), which was represented by
a greater incidence of foamy macrophage clusters (DES = 14%
vs. BMS = 0%, p < 0.001) as well as ﬁbroatheromas (DES = 13%
vs. BMS = 0%, p < 0.001). For durations between 2 and 6
years, the DES group still expressed a higher incidence of
neoatherosclerosis (DES = 41% vs. BMS = 22%, p = 0.053). A
multiple logistic generalized estimating equations modeling
identiﬁed younger age (odds ratio [OR] 0.963, 95% conﬁ-
dence interval [CI] 0.942 — 0.983; p < 0.001), longer implant
duration (OR 1.028, 95% CI 1.017 — 1.041; p < 0.001), Cypher
usage (OR 6.534, 95% CI 3.387 — 12.591; p < 0.001), Taxus
usage (OR 3.200, 95% CI 1.584 — 6.469; p = 0.001), and under-
lying unstable plaque (OR 2.387, 95% CI 1.326 — 4.302;
p = 0.004) as independent risk factors for neoatherosclerosis.
The occurrence of uncovered struts complicated by a dys-
functional endothelium remains the primary cause of LST in
DES, nevertheless this study adds another risk factor, i.e.
in-stent plaque rupture, although a rare event yet. While
the underlying processes responsible for the development
of neoatherosclerosis following stent implantation are likely
multifactorial, we hypothesize that it may involve the inabil-
ity to maintain a fully functional endothelialized luminal
e
t
S
ltions with Cypher stent implanted 13 months antemortem. A
ion within the intimal tissue is observed (D).
urface within the stented segment [32]. The endothelium
ormally provides an efﬁcient barrier against the excessive
ptake of circulating lipid and this may no longer be true
n the in-stent regions of DES [33]. Therefore, the divergent
echanisms where neoatherosclerosis attributed to DES may
e more related to incompetent and incomplete endothe-
ialization.
These ﬁndings were conﬁrmed in the clinical setting.
awakami et al. reported a case of newly developed yellow
eointima within Cypher implantation [34]. Another group
eported that coronary SES implants in 57 patients recently
nterrogated by angioscopy showed a 35% increase in the
aximum yellow color of the neointima within 10 months
f follow-up [35]. Even among lesions that did not express
ellow plaque at baseline, yellow color was detected in 95%
f SES implants, suggesting a neoatherosclerotic change in
esponse to the stent.
he timing of stent thrombosis and
echanisms
he mechanisms of stent thrombosis in DES have been
horoughly investigated by clinical and autopsy studies.
any factors are related to occurrence of stent thrombo-
is. In early phase (i.e. < 30 days), procedural factors are
ost likely responsible for stent thrombosis such as under-
xpansion, dissection at the stent edge, plaque rupture in
he residual atherosclerotic lesion, and medial fracture.
ince these complications are procedure related, the patho-
ogic ﬁndings in early stent thrombosis are similar between
90
Mechanisms of Stent Thrombosis in DES era
Delayed Healing
Procedure
Abnormal Vascular response
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Rigure 4 The timing and mechanisms of stent thrombosis in
he drug-eluting stent (DES) era.
arious stents including BMS. In fact, we have reported that
he cause of stent thrombosis was similar between Cypher
nd Taxus stents at autopsy of patients who died within 30
ays [12].
Whereas in the ‘‘late’’ phase (1—12 months), most stent
hrombosis occurs because of ‘‘delay’’ in arterial healing,
haracterized by uncovered stent struts and ﬁbrin deposi-
ion. As previously reported, it takes at most 3 months for
MS to be covered by endothelium, on the other hand, DES
akes longer to biologically recover which leads to ‘‘delayed
rterial healing’’. Initially, it was unclear how long this
‘delay’’ persists [10], but a recent autopsy study revealed
oth Cypher and Taxus does heal overtime especially in
atients with ‘‘on-label’’ usage [12].
The majority of DES showed relatively good coverage of
tent strut by neointimal tissue beyond 1 year from the
mplants. However, registry data published by Daemen et al.
ave demonstrated that a steady progressive increase of
tent thrombosis (0.6% per year) even after 1 year up to 5
ears [36]. Although the incidence was much lower in Japan,
imura et al. also reported a 0.2% increase each year in
tent thrombosis up to 3 years following SES implantation
37]. Therefore, it seems that mechanisms in addition to
elayed healing may be important in the pathophysiology of
tent thrombosis, especially beyond the period of ‘‘delayed
ealing’’. As we have reported, stent thrombosis due to
ypersensitivity reaction is usually seen beyond 1 year. Also
tent thrombosis secondary to extensive ﬁbrin deposition
ith or without stent malapposition in Taxus stents is often
bserved beyond 1 year. In addition, a recent ﬁnding of
‘neoatherosclerosis’’ may be responsible for occurrence
f very late stent thrombosis. Thus, the majority of very
ate stent thrombosis is likely associated with abnormal vas-
ular response such as hypersensitivity reaction, excessive
brin deposit, or neoatherosclerosis. Therefore, although
he incidence of stent thrombosis following DES implanta-
ion is similar in each period, the underlying mechanisms of
his complication may vary (i.e. early, late, and very late)
Fig. 4).
onclusion
ES result in delayed arterial healing which is associated
ith LST. Poor endothelialization is the most important
athologic predictor of LST along with the ratio of uncovered
o total stent struts. However, recent thorough investiga-
ions revealed additional mechanisms of stent thrombosis
[G. Nakazawa
uch as hypersensitivity reaction, excessive ﬁbrin deposit
ith malapposition, or neoatherosclerosis, which are asso-
iated with device speciﬁc components.
New technologies are being vigorously pursued and these
echnologies focus not only on the efﬁcacy, but also on the
afety aspects of the device. The FDA guidelines stated that
‘for any given drug devices combination, the potential efﬁ-
acy observed in animal studies should be balanced by any
otential safety’’ [38]. It is likely that the next generation
f intra-coronary devices will be safer, but we still need to
e cautious and keep surveying these devices carefully as
e have been doing so.
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